DOCSLIB.ORG

Case Report a Rare Case of Acute Lymphoblastic Leukemia in a Patient with Light Chain (AL) Amyloidosis Treated with Lenalidomide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case Report a Rare Case of Acute Lymphoblastic Leukemia in a Patient with Light Chain (AL) Amyloidosis Treated with Lenalidomide Int J Clin Exp Pathol 2014;7(5):2683-2689 www.ijcep.com /ISSN:1936-2625/IJCEP1402007 Case Report A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide Ranjit Nair1, Shereen Gheith2, Dan Popescu3, Nicole M Agostino3 1Department of Internal Medicine, Lehigh Valley Hospital and Health Network, Allentown, PA 18105, USA; 2Depart- ment of Pathology, Lehigh Valley Hospital and Health Network, Allentown, PA 18105, USA; 3Department of Hema- tology/Oncology, Lehigh Valley Hospital and Health Network, Allentown, PA 18105, USA Received February 3, 2014; Accepted April 3, 2014; Epub April 15, 2014; Published May 1, 2014 Abstract: Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leuke- mogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloido- sis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with lenalidomide and subsequently developed acute lymphoblastic leukemia. Keywords: Second primary malignancy, acute lymphoblastic leukemia, AL amyloidosis, lenalidomide Introduction Case Plasma cell neoplasms are characterized by A 73 year old female presented to our institu- clonal proliferation of plasma cells in the bone tion in the fall of 2007 with 3 month history of marrow leading to the production of monoclo- lower extremity edema. A routine complete nal immunoglobulins. They are sometimes blood count at the time of presentation showed accompanied by tissue deposition of monoclo- hemoglobin of 11.5 g/dL, normal WBC count, nal immunoglobulins or their components. and platelets 319,000/μL. Serum and urine Amyloidosis refers to a distinct group of tissue protein electrophoresis with immunofixation deposition disorders among which light-chain detected lambda light chains. A kidney biopsy (AL) amyloidosis is the most common type. The was obtained and showed multiple glomeruli with moderate to severe diffuse mesangial introduction of lenalidomide and other immu- expansion with accumulations of acellular, nomodulators (IMiDs) as a treatment modality weakly PAS positive material that shows red- for amyloidosis was a significant breakthrough green birefringence staining with Congo red in this disease. Multiple trials are ongoing with when examined under polarized light microsco- IMiDs in combination with other drugs for the py consistent with amyloid deposition (Figure treatment of AL amyloidosis [1]. There have 1). Immunofluorescent studies demonstrated been rare cases in which plasma cell neo- smudgy lambda light chain deposition in the plasms treated with lenalidomide develop interstitium and vessel walls. Kappa light chain acute leukemia post lenalidomide treatment was negative. The diagnosis of renal amyloido- and these cases were predominantly myelo- sis, AL lambda type involving glomeruli, intersti- blastic. We describe a rare incidence of tium and vessels was rendered. Bone marrow B-lymphoblastic leukemia in a patient with AL studies demonstrated a population of lambda amylodosis who received lenalidomide and light chain restricted plasma cells by flow dexamethasone for 56 months. cytometry. The bone marrow aspirate smears Acute leukemia in a lenalidomide treated amyloidosis patient g/dL. Review of peripheral blood smear showed numerous blasts. Bone marrow studies demonstrat- ed a markedly hypercellular mar- row with sheets of medium sized blast (Figure 2B). Flow cytometric studies showed an expanded B- lymphoblast population with dim CD45+, bright CD38, dim-moder- ate CD19, CD20, CD10, dim TdT, moderate CD34, variable CD33 and moderate-bright HLA-DR expr- ession, all consistent with a diag- nosis of B-lymphoblastic leukemia. FISH analysis showed copy gain of MYC and IGH in 13% of the nuclei, deletion of p53 gene in 76% of the cells, deletion of ABL gene in 79% Figure 1. Renal Biopsy with insert demonstrating amyloid deposits of the cells and low levels of copy showing birefringence on polarizing microscopy after Congo red stain- ing. gain for BCR (6.5%) and MLL genes (9%), monosomy 7 (79.5% of the cells), deletion of 20q (79.5% of showed trilineage hematopoiesis and with a the cells), tetrasomy 8 and copy gains for population of plasma cells, 5-8% of the total 5p/5q. There were no rearrangements for any cellularity (Figure 2A). Congo red stain was pos- studied probe set. Cytogenetic studies demon- itive for amyloid deposition. Cytogenetic and strated a normal karyotype: 46 XX. FISH (fluorescent in-situ hybridization) panel for multiple myeloma were within normal limits. The patient began induction chemotherapy These findings were compatible with lambda with daunorubicin, vincristine and prednisone light chain amyloidosis. and achieved a complete remission. Phase 2 of induction chemotherapy included cytoxan, Lenalidomide was started at 15 mg daily for 21 cytarabine, 6-mercaptopurine and intrathecal days, followed by 7 days off, for a 28 day total methotrexate [2]. Consolidation chemotherapy cycle. Dexamethasone was given at a dose of with high dose methotrexate was administered 20 mg weekly. She received aspirin for throm- and was complicated by an admission for infec- boembolic prophylaxis. At the initiation of treat- tion and bleeding. A few months after the com- ment, her serum lambda light chain level was pletion of consolidation chemotherapy, the 60 mg/dL. There was initially a flare in her patient unfortunately relapsed. Salvage chemo- lambda light chains to 101 mg/dL then the lev- therapy was attempted with vincristine and els started to improve. The patient achieved dexamethasone. Due to complications of her partial hematologic response with more than disease and treatment, she eventually devel- 50% reduction in the level of the serum mono- oped multi-organ failure and was put on com- clonal protein in less than 2 months and a com- fort measures. plete hematologic response with complete dis- appearance of the monoclonal protein in the Discussion serum in 7 months. The patient continued to be on the same regimen for a total duration of 56 It is estimated that more than 12 million cancer months. survivors are currently alive in the United States. Increasing survivorship has led to focus In November 2012, she presented with gener- on the long-term outcome of malignancies and alized weakness, lightheadedness and easy chemotherapy complications [3]. Lenalidomide bruising. On complete blood count the patient which is a less toxic and more potent derivative was found to have severe thrombocytopenia at of its parent drug, thalidomide, has renewed 16,000/μL. Her WBC count was normal at interest in the treatment of plasma cell dyscra- 5,600 cells/μL and the hemoglobin was 12.0 sias due to its significant therapeutic activity. 2684 Int J Clin Exp Pathol 2014;7(5):2683-2689 Acute leukemia in a lenalidomide treated amyloidosis patient Figure 2. A: Core bone marrow biopsy showing prominence of plasma cells consistent with AL amyloidosis. B: Bone marrow aspirate showing Acute Lymphoblastic Leukemia. Lenalidomide was examined in multiple phase with multiple myeloma who were treated with 2 studies for the treatment of AL amyloidosis in lenalidomide. However, the increased risk of a combination with other drugs. These trials SPM with lenalidomide was noted when the demonstrated favorable hematologic and drug was used in combination with alkylating organ response rates, manageable toxicity and agents. The hematologic malignancies found in no reported cases of second primary malignan- association with multiple myeloma were pre- cy (SPM) [4-9]. Lenalidomide, along with other dominantly acute myeloid leukemia or myelo- new targeted agents has dramatically improved dysplastic syndromes and a limited number of the overall median survival of patients with cases of B cell malignancies including acute amyloidosis to greater than 3 years [6, 9]. There lymphoblastic leukemia, Hodgkin and non- is a growing concern about an increasing num- Hodgkin lymphoma (NHL) [11, 12, 26]. ber of cases of SPMs associated with the use of lenalidomide in newly diagnosed and In a prospective double blind study by McCarthy relapsed multiple myeloma [10-12]. Though et al which compared the use of lenalidomide there are no reported cases of SPM in untreat- versus placebo for maintenance therapy after ed primary amyloidosis except for the limited autologous hematopoietic stem-cell transplan- number of cases reported of its delayed pro- tation in multiple myeloma, 8 cases of SPMs gression to multiple myeloma, it could be were reported in the lenalidomide group, two of debated that patients with untreated amyloido- which were NHL and ALL [12]. It is unclear as to sis do not survive long enough for other can- whether these 2 patients had received an alkyl- cers to develop [13]. We describe a patient with ating agent during the treatment course. The AL amylodosis who was treated with lenalido- rest of the malignancies were non-lymphoid in mide and dexamethasone. After 56 months of origin. A phase 3 placebo-controlled trial for treatment, she developed B-lymphoblastic leu- multiple myeloma by M. Attal et al, studied kemia. After thorough review of the literature, patients under the age of 65 years with non- we found no reports of B-cell acute lymphoblas- progressive disease who received consolida- tic leukemia occurring after a diagnosis of AL tion treatment with lenalidomide within six amyloidosis. months of autologous stem-cell transplanta- tion [11]. At a median follow-up of 34 months Before the advent of immunomodulators there from randomization and 44 months from diag- have been numerous cases of SPMs in multiple nosis, there were 32 SPMs in 26 patients myeloma, MGUS and Waldenström’s macro- reported in the lenalidomide group versus 12 globulinemia, but were predominantly of non SPMs in 11 patients in the placebo group.
Load more

Recommended publications
  • The Lymphoma and Multiple Myeloma Center
    The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J.
    [Show full text]
  • MYD88 L265P Is a Marker Highly Characteristic Of, but Not Restricted To, Waldenstro¨M’S Macroglobulinemia
    Leukemia (2013) 27, 1722–1728 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu ORIGINAL ARTICLE MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstro¨m’s macroglobulinemia C Jime´ nez1, E Sebastia´n1, MC Chillo´n1,2, P Giraldo3, J Mariano Herna´ndez4, F Escalante5, TJ Gonza´lez-Lo´ pez6, C Aguilera7, AG de Coca8, I Murillo3, M Alcoceba1, A Balanzategui1, ME Sarasquete1,2, R Corral1, LA Marı´n1, B Paiva1,2, EM Ocio1,2, NC Gutie´ rrez1,2, M Gonza´lez1,2, JF San Miguel1,2 and R Garcı´a-Sanz1,2 We evaluated the MYD88 L265P mutation in Waldenstro¨m’s macroglobulinemia (WM) and B-cell lymphoproliferative disorders by specific polymerase chain reaction (PCR) (sensitivity B10 À 3). No mutation was seen in normal donors, while it was present in 101/117 (86%) WM patients, 27/31 (87%) IgM monoclonal gammapathies of uncertain significance (MGUS), 3/14 (21%) splenic marginal zone lymphomas and 9/48 (19%) non-germinal center (GC) diffuse large B-cell lymphomas (DLBCLs). The mutation was absent in all 28 GC-DLBCLs, 13 DLBCLs not subclassified, 35 hairy cell leukemias, 39 chronic lymphocyticleukemias(16withM-component), 25 IgA or IgG-MGUS, 24 multiple myeloma (3 with an IgM isotype), 6 amyloidosis, 9 lymphoplasmacytic lymphomas and 1 IgM-related neuropathy. Among WM and IgM- MGUS, MYD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component (1.77 vs 2.72 g/dl, P ¼ 0.022), more lymphocytosis (24 vs 5%, P ¼ 0.006), higher lactate dehydrogenase level (371 vs 265 UI/L, P ¼ 0.002), atypical immunophenotype (CD23 À CD27 þþFMC7 þþ), less Immunoglobulin Heavy Chain Variable gene (IGHV) somatic hypermutation (57 vs 97%, P ¼ 0.012) and less IGHV3–23 gene selection (9 vs 27%, P ¼ 0.014).
    [Show full text]
  • Plasma Cells Leukemia Masquerading As Lymphocyte-Monocyte Peak on Automated Cell Analyzer Dr
    Saudi Journal of Pathology and Microbiology Abbreviated Key Title: Saudi J Pathol Microbiol ISSN 2518-3362 (Print) |ISSN 2518-3370 (Online) Scholars Middle East Publishers, Dubai, United Arab Emirates Journal homepage: https://saudijournals.com Case Report Plasma Cells Leukemia Masquerading as Lymphocyte-Monocyte Peak on Automated Cell Analyzer Dr. Akshita Rattan1*, Dr. Anita Tahlan2, Dr. Swathi C Prabhu2, Dr. Sanjay D'Cruz3 1Junior Resident, Department of Pathology, Government Medical College Sector-32, Chandigarh, India 2Department of Pathology, Government Medical College Sector-32, Chandigarh, India 3Department of Dermatology, Government Medical College Sector-32, Chandigarh, India DOI: 10.36348/sjpm.2021.v06i02.006 | Received: 03.02.2021 | Accepted: 14.02.2021 | Published: 16.02.2021 *Corresponding author: Dr. Akshita Rattan Abstract Background: Peripheral blood plasmacytosis can be seen in plasma cell leukemia (PCL) or plasma cell myeloma (PCM). As plasma cells show dysplasia or lymphocytoid morphology, they masquerade as monocytes or high fluorescent lymphocytes (HFL) on automated cell analyzer. The early suspicion and detection are of clinical importance for diagnostic and prognostic reasons. Methods: Automated cell analyzer was used for routine CBC examination. Peripheral blood smear examination was performed for enumeration and characterization of cells in peripheral blood followed by bone marrow examination and ancillary techniques. Conclusion: Lymphocyte-Monocyte peak with increased high HFL count on CBC should prompt a smear
    [Show full text]
  • POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: a Case Report and Review of the Literature
    Open Access Annals of Hematology & Oncology Special Article - Hematology POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: A Case Report and Review of the Literature Kasi Loknath Kumar A1,2*, Mathur SC3 and Kambhampati S1,2* Abstract 1Department of Hematology and Oncology, Veterans The coexistence of B-cell Chronic Lymphocytic Leukemia/Small Affairs Medical Center, Kansas City, Missouri, USA Lymphocytic Lymphoma (CLL/SLL) and Plasma Cell Dyscrasias (PCD) has 2Department of Internal Medicine, Division of rarely been reported. The patient described herein presented with a clinical Hematology and Oncology, University of Kansas Medical course resembling POEMS syndrome. The histopathological evaluation Center, Kansas City, Kansas, USA of the bone marrow biopsy established the presence of an osteosclerotic 3Department of Pathology and Laboratory Medicine, plasmacytoma despite the absence of monoclonal protein in the peripheral Veterans Affairs Medical Center, Kansas City, Missouri, blood. Cytochemical analysis of the plasmacytoma demonstrated monotypic USA expression of lambda (λ) light chains, a typical finding associated with POEMS *Corresponding authors: Kambhampati S and Kasi syndrome. A subsequent lymph node biopsy performed to rule out Castleman’s Loknath Kumar A, Department of Internal Medicine, disease led to an incidental finding of B-CLL/SLL predominantly involving the Division of Hematology and Oncology, University of B-zone of the lymph node. The B-CLL population expressed CD19, CD20, CD23, Kansas Medical Center, Kansas City, 2330 Shawnee CD5, HLA-DR, and kappa (κ) surface light chains. To the best of our knowledge, Mission Parkway, MS 5003, Suite 210, Westwood, KS, a simultaneous manifestation of CLL/SLL and POEMS has not been previously 66205, Kansas, USA, Tel: 9135886029; Fax: 9135884085; reported in the literature.
    [Show full text]
  • Solitary Plasmacytoma: a Review of Diagnosis and Management
    Current Hematologic Malignancy Reports (2019) 14:63–69 https://doi.org/10.1007/s11899-019-00499-8 MULTIPLE MYELOMA (P KAPOOR, SECTION EDITOR) Solitary Plasmacytoma: a Review of Diagnosis and Management Andrew Pham1 & Anuj Mahindra1 Published online: 20 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Solitary plasmacytoma is a rare plasma cell dyscrasia, classified as solitary bone plasmacytoma or solitary extramedullary plasmacytoma. These entities are diagnosed by demonstrating infiltration of a monoclonal plasma cell population in a single bone lesion or presence of plasma cells involving a soft tissue mass, respectively. Both diseases represent a single localized process without significant plasma cell infiltration into the bone marrow or evidence of end organ damage. Clinically, it is important to classify plasmacytoma as having completely undetectable bone marrow involvement versus minimal marrow involvement. Here, we discuss the diagnosis, management, and prognosis of solitary plasmacytoma. Recent Findings There have been numerous therapeutic advances in the treatment of multiple myeloma over the last few years. While the treatment paradigm for solitary plasmacytoma has not changed significantly over the years, progress has been made with regard to diagnostic tools available that can risk stratify disease, offer prognostic value, and discern solitary plasmacytoma from quiescent or asymptomatic myeloma at the time of diagnosis. Summary Despite various studies investigating the use of systemic therapy or combined modality therapy for the treatment of plasmacytoma, radiation therapy remains the mainstay of therapy. Much of the recent advancement in the management of solitary plasmacytoma has been through the development of improved diagnostic techniques.
    [Show full text]
  • A Diagnostic Conundrum
    Open Access Case Report DOI: 10.7759/cureus.16832 Leucocytoclastic Vasculitis, Cryoglobulinemia, or Plasma Cell Leukemia: A Diagnostic Conundrum Hycienth Ahaneku 1 , Ruby Gupta 1 , Nwabundo Anusim 1 , Chukwuemeka A. Umeh 2 , Joseph Anderson 3 , Ishmael Jaiyesimi 1 1. Hematology and Oncology, Beaumont Health, Royal Oak, USA 2. Internal Medicine, Beaumont Health, Hemet, USA 3. Hematology and Oncology, Beaumont Health, Royal Oak, USA Corresponding author: Hycienth Ahaneku, [email protected] Abstract Plasma cell leukemia is rare and could be life-threatening. Even rarer and equally life-threatening is cryoglobulinemia. Both of them occurring together paints a grim clinical picture. We present the case of a 63-year-old male with plasma cell leukemia complicated by cryoglobulinemia with skin lesions. The report briefly reviews the clinical and diagnostic characteristics of plasma cell leukemia and well as available treatment options. It also highlights the need to consider non-chemotherapy-based regimens and clinical trials in the care of plasma cell leukemia patients. Categories: Oncology, Rheumatology, Hematology Keywords: plasma cell leukemia, cryoglobulinemia, multiple myeloma, bortezomib, lenalidomide, autologous stem cell transplant Introduction Plasma cell dyscrasias are a group of hematologic malignancies characterized by clonal proliferation of plasma cells. They cover a spectrum ranging from the premalignant monoclonal gammopathy of undetermined significance (MGUS) to the more aggressive multiple myeloma (MM) and plasma cell leukemia (PCL). PCL is often seen as the most aggressive plasma cell neoplasm. PCL accounts for less than 4% of plasma cell neoplasms and its population incidence is about one in a million, making it one of the rarest of plasma cell neoplasms [1].
    [Show full text]
  • Clinicopathological Study of Spectrum of Plasma Cell Dyscrasias in a Tertiary Care Centre-Retrospective Four Year Study
    Indian Journal of Pathology and Oncology 2020;7(1):158–163 Content available at: iponlinejournal.com Indian Journal of Pathology and Oncology Journal homepage: www.innovativepublication.com Original Research Article Clinicopathological study of spectrum of plasma cell dyscrasias in a tertiary care centre-retrospective four year study Sindhu Sharma1, Jyotsna Suri1,*, Bhavneet Kour1 1Dept. of Pathology, Government Medical College, Jammu, Jammu & Kashmir, India ARTICLEINFO ABSTRACT Article history: Plasma Cell Dyscrasias (PCD) by definition are represented by excessive proliferation of a single clone Received 30-08-2019 of cells producing entire immunoglobulins, immunoglobulin fragments, heavy chains or light chains. Accepted 05-09-2019 These encompass a wide range of disorders. In this study we try to discuss the clinical and pathological Available online 22-02-2020 characteristics of this rare but important group of hematological malignancies. Materials and Methods: This study was carried out in a tertiary care centre retrospectively for a period of four years. All the cases diagnosed with Plasma Cell Dyscrasias were selected. They were re-evaluated Keywords: taking into consideration clinical aspects, radiological findings and blood and bone marrow examinations. Multiple myeloma These were further categorized using Salmon Durie Staging system. Plasma cell dyscrasia Results: During this study a total of 41 cases fulfilled the diagnostic criteria of Plasma Cell Dyscrasias. Waldenstrom’s macroglobulinemia Among them 33 were newly diagnosed cases of Multiple Myeloma, 4 cases were of relapse and 4 were of Waldenstrom’s Macroglobulinemia’s. Males outnumbered females in our study. The most common complaint was anemia (seen in 90% of cases) followed by lytic bone lesions and presence of M Band on electrophoresis.
    [Show full text]
  • Waldenström Macroglobulinemia Irene M
    Waldenström Macroglobulinemia Irene M. Ghobrial, MD Thomas E. Witzig, MD* Address *Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. E-mail: [email protected] Current Treatment Options in Oncology 2004, 5:239–247 Current Science Inc. ISSN 1527-2729 Copyright © 2004 by Current Science Inc. Opinion statement Waldenström macroglobulinemia (WM) is a low-grade lymphoproliferative disorder charac- terized by the presence of an immunoglobulin M monoclonal protein in the blood and monoclonal small lymphocytes and lymphoplasmacytoid cells in the marrow. The disease is uncommon and there is a lack of clear diagnostic criteria. WM is treatable but not curable and long-term survival is possible. Therefore, the treating physician needs to carefully bal- ance the risks and benefits of treatment. Treatments are aimed at relieving symptoms resulting from marrow infiltration and the hyperviscosity syndrome. Therapies available for initiation of treatment include alkylating agents, purine nucleoside analogs, and ritux- imab. Chlorambucil has been the mainstay of treatment for many years and remains useful, especially in older patients. Rituximab has become an important new therapy for this dis- ease because of its positive treatment responses, acceptable toxicity, and lack of therapy- associated myelosuppression and myelodysplasia. Currently, rituximab is being combined with chemotherapy. Other options of treatment include interferon and corticosteroids. Emerging therapies include stem cell transplantation (autologous and allogeneic) for younger patients. Currently, there are few comparative data on which to state an absolute opinion concerning the best available treatment for patients with WM. Introduction Waldenström macroglobulinemia (WM) was first described approximately 25% of cases and are not nearly as promi- by Jan Waldenström in 1944 [1] and is classified in the nent as found in non-Hodgkin lymphoma.
    [Show full text]
  • Advancing the Management of Plasma Cell Dyscrasias
    Advancing the Management of Plasma Cell Dyscrasias Rachid Baz, MD Moffitt Cancer Center Beth Faiman, PhD, MSN, APRN-BC, AOCN® Cleveland Clinic Learning Objectives • Interpret differential diagnoses of plasma cell dyscrasias • Assess recent changes in clinical management of the spectrum of multiple myeloma (smoldering, monoclonal gammopathy of undetermined significance [MGUS]) • Evaluate the risks and benefits of early treatments for smoldering myeloma • Plan management strategies for patients with solitary plasmacytomas and amyloidosis Financial Disclosure • Dr. Faiman has acted as a consultant and served on the speakers bureau for Amgen and Takeda; she has served on the speakers bureau for Celgene and Janssen. • Dr. Baz has received research support from AbbVie, Bristol- Myers Squibb, Celgene, Karyopharm, Merck, and Takeda; he has received honoraria from Celgene. All Blood Cells Begin as Hematopoietic Stem Cells Natural killer Healthy Bone Marrow Neutrophils (NK) cells Lymphoid progenitor T lymphocytes Basophils cell B lymphocytes Eosinophils Hematopoietic Multipotential Myeloid Monocytes/ stem cell stem cell progenitor cell macrophages Platelets Red blood cells NIH Stem Cell Information website. Based on: https://stemcells.nih.gov/info/basics/4.htm. Plasma Cell Disorders: Distribution of Plasma Cell Dyscrasias N = 1,296 SMM 3.5% (44) Lymphoproliferative Solitary or extramedullary 2.5% 1.5% AL Amyloidosis 10% Macro 3% Other 2.5% Myeloma 15% MGUS 62% AL = amyloidosis; MGUS = monoclonal gammopathy of uncertain significance; SMM = smoldering
    [Show full text]
  • Plasma Cell Disorders
    Paraproteinaemias. Multiple myeloma. Amyloidosis. Gabor Mikala MD, PhD South-Pest Central Hosp, Nat. Inst. Hematol. Infectol. Dept. Hematology & Stem Cell Transplantation Slide credits to Anwar Kahlon, MD Subtypes of Plasma Cell Disorders • Increased Plasma Cells and Paraproteins – Monoclonal Gammopathy (of unknown significance, MGUS) – Multiple Myeloma (MM) – Waldenström’s Macroglobulinemia (WM, IgM) • Increased / Altered Products of Plasma Cells (that may be few) – Light Chain Amyloidosis – Light Chain Deposition Disease B cell Development As a Framework for Malignancies Lymphoplasmacyte IgM Lymph node Germinal Center SOMATIC Lymphoblast HYPERMUTATION Plasmablast SWITCH RECOMBINATION Virgin B cell V(D)J RECOMBINATION Bone G,A,E Plasma cell Marrow Pre-B cell B cell Development As a Framework for Malignancies Lymphoplasmacyte IgM WALDENSTROM’S Lymph node Germinal Center SOMATIC Lymphoblast HYPERMUTATION BURKITT’S Plasmablast FOLLICULAR LYMPHOMA LYMPHOMA Virgin B cell CLL MULTIPLE Bone G,A,E Plasma cell ALL MYELOMA Marrow Pre-B cell Case Presentation • 48 yo male • Admitted with 2 wk history of fatigue and diffuse bone pain • Evaluation: – Increased serum creatinine 500 umol/l – Increased serum calcium 2.9 mmol/l – Increased serum globulin 50 g/l (normal < 30 g/l) Evaluation of Abnormal Serum Globulins Serum Urine Serum/Urine Protein Immunofixation Electrophoresis (S/UPEP) Electrophoresis (IFE) Serum M spike 40 g/l ; typed as IgG kappa monoclonal Ig Case Presentation…cont’d Bone Marrow biopsy- Increased plasma cells Skeletal survey—Lytic bone disease Clinical spectrum of clonal expansions of transformed plasma cells in patients • Stable intramedullary expansion (benign?) •Asymptomatic (sometimes not so) MGUS (premalignant) Normal Transformed cell Cell • Progressive intramedullary expansion. • Anemia, bone pain, infections • Lytic bone disease.
    [Show full text]
  • Concomitant Diagnosis of Plasma Cell Leukemia in Patient with JAK2 Positive Myeloproliferative Neoplasm
    Thomas Jefferson University Jefferson Digital Commons Division of Internal Medicine Faculty Papers & Presentations Division of Internal Medicine 1-1-2020 Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm. Christine J Kurian Thomas Jefferson University Colin Thomas Thomas Jefferson University Sarah Houtmann Thomas Jefferson University Thomas Klumpp Thomas Jefferson University Follow this and additional works at: https://jdc.jefferson.edu/internalfp Adam Finn Binder Thomas Part ofJeff theerson Internal Univ Medicineersity Commons Let us know how access to this document benefits ouy Recommended Citation Kurian, Christine J; Thomas, Colin; Houtmann, Sarah; Klumpp, Thomas; and Binder, Adam Finn, "Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm." (2020). Division of Internal Medicine Faculty Papers & Presentations. Paper 37. https://jdc.jefferson.edu/internalfp/37 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. CASE REPORT published: 27 August 2020 doi: 10.3389/fonc.2020.01497 Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm Christine J.
    [Show full text]
  • Plasma Cell Dyscrasias and Plasma Cell Leukaemia
    P.O. Box 131375, Bryanston, 2074 Ground Floor, Block 5 Bryanston Gate, Main Road Bryanston, Johannesburg, South Africa www.thistle.co.za Tel: +27 (011) 463-3260 Fax: +27 (011) 463-3036 OR + 27 (0) 86-557-2232 e-mail : [email protected] Please read this section first The HPCSA and the Med Tech Society have confirmed that this clinical case study, plus your routine review of your EQA reports from Thistle QA, should be documented as a “Journal Club” activity. This means that you must record those attending for CEU purposes. Thistle will not issue a certificate to cover these activities, nor send out “correct” answers to the CEU questions at the end of this case study. The Thistle QA CEU No is: MT-2015/009. Each attendee should claim THREE CEU points for completing this Quality Control Journal Club exercise, and retain a copy of the relevant Thistle QA Participation Certificate as proof of registration on a Thistle QA EQA. DIFFERENTIAL SLIDES LEGEND CYCLE 46 SLIDE 2 – MARCH 2015 PLASMA CELL DYSCRASIAS AND PLASMA CELL LEUKAEMIA Plasma Cell Dyscrasias Plasma cell dyscrasias are disorders of the plasma cells. Plasma cell dyscrasias are produced as a result of abnormal proliferation of a monoclonal population of plasma cells that may or may not secrete detectable levels of a monoclonal immunoglobulin or immunoglobulin fragment (paraprotein or M protein). Although the most common plasma cell dyscrasia is monoclonal gammopathy of undetermined significance (MGUS), closely related disorders include multiple myeloma, solitary plasmacytoma of bone, extramedullary plasmacytoma, Waldenström's macroglobulinemia (WM), primary amyloidosis, light chain deposition disease, paraproteinemia, and heavy-chain disease.
    [Show full text]